| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() European Authorities Recognize Approval Of Zomig Rapimelt EDEN PRAIRIE, MN -- November 23, 1999 -- CIMA LABS INC. announces that ten European regulatory authorities have agreed to mutually recognize the Swedish approval of Zomig Rapimelt, the OraSolv(R) fast-dissolving version of the AstraZeneca anti-migraine medication. This follows the launch in Sweden earlier in the year.
OraSolv is a patented oral dosage form which incorporates microencapsulated drug ingredients into tablets that dissolve quickly in the mouth. OraSolv is designed to improve taste acceptance and address the difficulty of swallowing traditional tablets and capsules, while offering a convenient oral dosage form that can be taken anywhere and anytime, therefore increasing compliance. CIMA is a drug delivery company that specializes in oral drug delivery systems to improve patient compliance and drug efficacy. These systems include OraSolv, OraSolv SR/CR and DuraSolv, fast-dissolve technologies, and OraVescent, a dual fast-dissolve/oral transmucosal system for improved oral absorption, targeted site-specific absorption and fast onset of action.
Related Links: Zomig Rapimelt and AstraZeneca .
|